Cereno Scientific announces extended patent protection in Europe for CS585 program
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that a patent has been approved (Notice of Allowance) in the first patent family for the preclinical Prostacyclin Receptor Agonist program, which includes drug candidate CS585. The patent expands the patent protection for the Prostacyclin Receptor Agonist program to also include Europe, one of the largest markets for cardiovascular disease.“I am pleased to announce the second patent in Europe for our preclinical Prostacyclin